Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283473 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Ming-Chen Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Biology, R&D Division, OBI Pharma. Inc., Taipei, Taiwan. Hauptthemen laut MEDLINE: ISCOMs, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Biology, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
- Department of Pharmacology, Pharmacokinetics, and Toxicology, R&D Division, OBI Pharma. Inc, Taipei, Taiwan.
- Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
- Department of CMC, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
- Department of Biologics Discovery, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
- CEO Office, OBI Pharma. Inc., Taipei, Taiwan.
ORCID-Profile: Ming-Chen Yang, Ming-Tain Lai
Zitieren
APA
Yang, M. C., Wang, C. C., Tang, W. C., Chen, K. M., Chen, C. Y., Lin, H. H., Hsieh, Y. C., Wang, N. H., Kuo, Y. C., Chu, P. T., Tung, H. Y., Wu, Y. C., Sun, J. L., Liu, S. Y., Li, W. F., Lee, W. H., Lai, J. S., Chang, M., & Lai, M. T. (2023). Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. PLOS ONE. https://doi.org/10.1371/journal.pone.0283473
Vancouver
Yang MC, Wang CC, Tang WC, Chen KM, Chen CY, Lin HH, et al. Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. PLOS ONE. 2023. doi:10.1371/journal.pone.0283473
BibTeX
@article{Yang2023,
author = {Yang, Ming-Chen and Wang, Chun-Chung and Tang, Wei-Chien and Chen, Kuan-Ming and Chen, Chu-Ying and Lin, Hsiao-Han and Hsieh, Yin-Cheng and Wang, Nan-Hsuan and Kuo, Yin-Chieh and Chu, Ping-Tzu and Tung, Hsin-Yi and Wu, Yi-Chen and Sun, Juo-Ling and Liu, Sheng-Yu and Li, Wan-Fen and Lee, Wei-Han and Lai, Jiann-Shiun and Chang, Michael and Lai, Ming-Tain},
title = {Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283473}
}
EUVIMED